STUDresearch · Peptide
Chonluten
Also known as
EDG peptide · Glu-Asp-Gly · Glutamyl-aspartyl-glycine · H-Glu-Asp-Gly-OH · T-34 · T-34 tripeptide · T34 · lung bioregulator · bronchial bioregulator · Honluten · Khonluten · Chonluten Cytogen · Chonluten (Cytomax / bioregulator capsule discussions) · Khavinson lung peptide · bronchopulmonary bioregulator
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Oral / sublingual / SubQ
Longevity & bioregulators
Whole-body — people treat this as circulating, not a local pin.
What people say
Chonluten is the synthetic EDG tripeptide sold as a bronchopulmonary bioregulator. It is not Bronchogen/AEDL or the animal-tissue Taxorest complex, and evidence from those products should not be transferred to it.
Doses people talk about
Sequence, route, form and unit must stay attached to each row; none of the ranges is a validated respiratory-treatment dose.
How it may feel
Reports frame any breathing change as gradual and subtle, with many people noticing nothing. In one stacked Chonluten-plus-Bronchogen account, the same author reported no breakthrough around two weeks, then deeper breaths and less nighttime cough around four weeks while some shortness of breath remained.
Classic oral Cytogen chart10 mg capsule once daily for 10–20 days
Common traditional product figure, not interchangeable with injectable EDG powder.
Oral variants10–20 mg/day for about 10–30 days
Secondary product-page range, including some 20 mg/day discussion.
Sublingual product talk5–6 drops, three or four times daily before meals
Brand- and formulation-specific drop language; not convertible to capsule milligrams from the available notes.
Injectable microgram charts250–4,000 mcg/day, usually shown once daily
A very wide vendor/reference band whose upper end is not a validated target.
Conflicting multi-milligram charts5–10 mg SubQ daily for 10–20 days, or about 2 mg/day in pen-style talk
A separate high-amount culture with recurring mg-versus-mcg and product-form confusion.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- One Chonluten + Bronchogen accountNo breakthrough at about 2 weeks; easier breathing and less nighttime cough around 4 weeks
Cycles people discuss
The legacy record contains separate cultures: 10–20-day oral blocks, 10-day injectable pulses and 8–16-week injectable charts. These cannot be treated as one validated calendar.
Timing
Morning oral or sublingual use before food appears in community notes, but capsule charts also describe use with meals. Injectable charts usually use once-daily SC at varied times of day. These form-specific habits have no established morning-versus-evening advantage and are not interchangeable schedules.
Stacks
Bronchogen and Taxorest are the dominant lung-family pairing or sequence names. Their different identities and the lack of head-to-head trials make single-agent attribution especially weak.
Watch for
Dose-chart chaos: 200 mcg short courses, 250–1,500 mcg multi-week charts, multi-mg bioregulator figures, and oral 10 mg capsules are not interchangeable — unit errors are a real harm vector.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A bodily half-life for Chonluten/EDG was not established by the reviewed sources.
The accessible primary paper exposed THP-1 cells overnight to 100 ng/mL Chonluten. That is an in-vitro signaling experiment, not animal or human absorption, distribution or elimination evidence.
No human or animal ADME data were present in the reviewed paper; culture concentration cannot be converted into a human dose or half-life.
- Avolio et al. — Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line (opens in a new tab)Materials and Methods sections 4.1–4.2 and results section 2.3: Chonluten P5 is Glu-Asp-Gly; THP-1 cells were exposed overnight at 100 ng/mL, with and without LPS.In-vitro monocyte/macrophage work, not airway tissue, spirometry, an administered product, or human/animal pharmacokinetics.
Felt duration people report
No repeatable per-dose felt-duration window was established. One stacked account reported no breakthrough at about two weeks, then a course-level breathing change at about four weeks.
The same author first reported no breakthrough at roughly two weeks, then reported deeper breaths, less nighttime cough and fluid, and readiness to begin cardio after roughly four weeks of Chonluten plus Bronchogen, while occasional shortness of breath remained.
Single self-report, two-peptide stack, no dose, no objective lung testing and substantial illness, medication and activity confounding.
- Bronchogen bioregulator dosage — Chonluten follow-up (opens in a new tab)Same-author updates: at about two weeks the user reported no breakthrough; at about four weeks the user reported deeper breaths, less nighttime cough/fluid, occasional shortness of breath remaining, and intent to begin cardio while using Chonluten plus Bronchogen.Unverified products, two-agent stack, no dose or route in the inspected updates, no comparator, no spirometry and no adverse-event follow-up; two course checkpoints do not establish per-dose duration.
- Chonluten — CosmicNootropic community discussion (opens in a new tab)Post body: user stacked Chonluten and Bronchogen in the setting of asthma and smoking/vaping history and said breathing was definitely improving; replies discuss conflicting oral and injectable product charts.Vendor-adjacent forum, stacked products, concurrent albuterol history, no objective measurement and no clean timing or single-agent attribution.
What people say
- Breathing comfort (community): Multi-week logs of slightly easier breathing, less chest tightness, or quieter stairs — usually described as subtle if present at all. forum
- COPD / chronic bronchitis adjunct: Marketed and discussed as complementary support while staying on guideline therapy; no solid Western RCTs for Chonluten itself. forum
- Asthma adjunct lore: Occasional claims of fewer flares or less bronchial irritation over courses — continue controllers/rescue; not a rescue substitute. anecdote
- Post-viral / post-COVID recovery: Growing forum interest for residual inflammation, breathlessness, or “lung recovery” after infection clears — heavily confounded by time, rehab, and stacks. anecdote
- Smoking / vaping talk: Less irritation or “clearing smoker’s cough” narratives in secondary blogs; no controlled human outcome data, and some Russian-protocol summaries discourage expecting repair while still smoking. anecdote
- Exercise / oxygen lore: Secondary athletic blogs claim better aerobic capacity or less mid-cardio wind — evidence quality is low and confounded. anecdote
- Stack halo problem: Inside multi-bioregulator kits or with Bronchogen/BPC, single-agent credit is weak; users often attribute any breathing change to the whole stack. forum
- What community realism discounts: MRI/CT reversal of fibrosis, replacing oxygen or biologics, or FEV1 miracle gains without measured spirometry logs. forum
- In-vitro cytokine (Avolio 2022): At 100 ng/mL in THP-1 models, peptides including Chonluten reduced LPS-driven TNF, IL-6, and (with class peers) IL-17 signals and lowered monocyte adhesion to LPS-activated endothelium. lab
- Mild TNF “tolerance” hook: Authors discuss modest basal TNF release with Chonluten on monocytes as a possible anergy/tolerance angle — mechanistic speculation from culture, not patient outcomes. lab
- Apoptosis note (same paper): Chonluten uniquely nudged a higher apoptotic fraction in THP-1 cycle analysis versus some peer peptides — still in-vitro only. lab
- Gene-expression / antioxidant literature (developer-linked): Secondary summaries cite modulation of antioxidant and inflammatory genes (e.g., SOD-class, TNF-α, Cox-2, HSP70) in tissue models, including gastric-mucosa work — not the same as human lung repair trials. lab
- Developer review claims (unverified detail): Khavinson-group reviews allude to enhanced standard therapy in chronic bronchitis with asthmatic component and hypoxia performance indices — underlying reports often lack PubMed-indexed trial structure, N, or comparators. trial
- Feel profile: Gradual “tissue support” framing, not same-day bronchodilator open-air feel; many report no detectable change after 1–2 courses. forum
- STAT framing (same paper): Chonluten among peptides activating STAT1 phosphorylation with a possible mild STAT3 attenuation story under LPS co-challenge — cell signaling, not clinical anti-inflammation proof. lab
Doses people talk about
- Classic Russian-style oral Cytogen: ~10 mg capsule once daily for ~10–20 consecutive days is the most-repeated traditional figure (10–20 capsules per cycle when each is 10 mg). forum
- Oral range variants: Product/secondary pages also cite ~10–20 mg/day totals and courses of ~10–30 days; some intensive talk uses 2 × 10 mg capsules once daily (~20 mg/day). forum
- Aggressive oral blog protocols: Influencer-style writeups sometimes push 1–2 capsules once daily before breakfast, or 2 capsules twice daily with meals for “faster” results — higher than the classic 10 mg × 10 day calendar and not trial-anchored. forum
- Sublingual product talk: Secondary guides mention ~5–6 drops under the tongue, held briefly, 3–4× daily before meals — form- and brand-specific, not interchangeable with 10 mg capsules by drop count alone. forum
- Annual oral cadence: ~2–3 short courses/year with multi-month breaks (often ~2–6 months off); spring and fall timing is popular around respiratory seasons. forum
- Wider mcg band: Reference protocol pages also quote roughly 250–4,000 mcg/day once daily — upper end is chart max, not a validated therapeutic target. forum
- High multi-mg injectable talk (conflict zone): Occasional guides list ~5–10 mg SC daily for 10–20 days in bioregulator “classic multi-mg” style, or pen-style ~2 mg/day (e.g., “20 units” language on prefilled pens) — orders of magnitude above the 200–1,500 mcg Western mid charts; mg-vs-mcg mix-ups and brand-form confusion are recurring warnings. forum
- Vial coverage math (mid chart): At ~0.5–1 mg/day, one 20 mg vial covers roughly ~20–40 days; multi-month titration courses may need multiple vials. forum
- Vial coverage math (200 mcg × 10 d): At 200 mcg/day a 20 mg vial theoretically holds many 10-day courses if fully used — chart-dependent and purity-dependent. forum
- Oral vs injectable culture split: Oral Cytogen capsules dominate Cosmic/nootropic and bioregulator retail; research-chem lyophilized vials dominate peptide-forum inject culture — logs are not dose-comparable by brand name alone. forum
- Timing habits: Empty-stomach morning oral or sublingual hold is common; injectable once-daily SC any time of day is the usual default — no controlled chronotherapy data. forum
- Uncertainty rule: Always resolve sequence (EDG), form (oral Cytogen vs cytomax complex vs lyophilized powder), and unit (mg vs mcg) before comparing community logs. forum
- Label / identity risk: EDG vs Bronchogen (AEDL) vs mislabeled Glu-Asp-Leu pages mean labeled mg may not equal verified EDG; COA/MS checks are stressed for short peptides. forum
- Framing: Community, vendor-chart, and product-label ranges only — not prescriptions, not trial-established human doses. No ClinicalTrials.gov dose standard exists for Chonluten. forum
How it may feel
- Days 1–3: Usually no acute lung feel; oral GI awareness or injection-site sting more common than “opened airways.” forum
- Days 4–10 (classic short course): Still often nothing obvious; gene-regulation culture expects delayed, subtle shifts — hard to separate from placebo, weather, meds, or quitting smoking. forum
- End of 10–20 day oral block: Primary community checkpoint — slightly easier breathing vs “subtle/absent”; many end here without escalation. forum
- Weeks 2–4: End of typical Cytogen oral course window; some claim quieter stairs or less morning tightness; spirometry logs remain rare in public threads. forum
- Weeks 4–8 off-course: Bioregulator lore says effects can continue after levels fall; public logs rarely track FEV1/FVC or 6-minute walk with controls. forum
- Weeks 8–16 (Western injectable titration charts): Vendor mid charts that titrate 250→1,500 mcg over multi-month windows are judged slowly; still not inhaler-speed. forum
- Months 2–6 with re-runs: Clearer stories (when they exist) often involve 2–3 seasonal courses plus real pulmonary care — single-cycle miracles are minority claims. anecdote
- Post-viral recovery windows: Anecdotes sometimes span 1–3 months of cyclic use after acute illness resolves; natural recovery confounds attribution. anecdote
Cycles people discuss
- Short oral blocks dominate classic culture: 10–20 consecutive days on, then multi-month off, is the standard Khavinson-style oral calendar. forum
- Extended oral intensives: Some secondary protocols describe initial 1–3 month use or 10–30 day courses before maintenance pulses every ~3–6 months — longer than the classic 10-day cytogen insert pattern. forum
- Western injectable windows: Vendor mid charts run daily SC for ~8–16 weeks with gradual titration — a different culture from 10-day capsule courses. forum
- Short injectable intensive: Alternate charts keep the bioregulator 10-day pulse (~200 mcg/day) with ~4–6 months between courses. forum
- Seasonal timing: Spring (e.g., Mar–Apr) and fall (Sep–Oct) re-runs are commonly discussed; optional pre-winter pulse appears in longevity calendars. forum
- Why cyclic, not continuous: Bioregulator theory frames short peptides as gene-expression signals that may persist after exposure ends — opposite of continuous controller inhalers or long injury-peptide runs. forum
- Continuous daily: Minority practice for research-chem injectables; generally treated as non-standard vs classic calendars and lacks safety DB. forum
- Re-start triggers: Seasonal symptoms, post-illness recovery after acute phase resolves, high pollution/travel seasons, or multi-organ “bioregulator weeks.” forum
- Sequential lung stack scheduling: Forum advice sometimes runs Bronchogen and Chonluten as separate 10-day courses with ~2 weeks between for cleaner tracking; Taxorest (cytomax) is often discussed after a synthetic cytogen block. forum
- Multi-year gray-market safety: Long-horizon controlled safety datasets for research-powder Chonluten are lacking even when Russian product use is described as long-standing. trial
Timing
- Class assumption: Ultrashort tripeptides face rapid proteolysis and short plasma residence → daily dosing while on-course is practice-driven, not PK-proven steady state. forum
- Oral bioavailability fight: Oral convenience dominates retail, but inject culture assumes higher bioavailability; sublingual hold is the middle-ground tweak — none of these ranks are from controlled EDG human BA studies. forum
- Pulsed logic: Brief exposure, longer claimed gene/tissue effects after levels fall — core bioregulator lore, unproven specifically for EDG in humans. forum
- Feel vs blood: Benefit talk is gradual multi-week tissue support, not acute on/off drug feel when a dose is missed. anecdote
- Injectable timing: Once-daily subq is the research-chem default; no head-to-head morning vs evening lung outcome data. forum
- Human PK gap: No published ADME package (half-life, bioavailability, distribution, metabolism) for Chonluten in animals or humans is widely cited. trial
- Only published exposure anchor: The 2022 THP-1 work used 100 ng/mL in culture — that concentration does not convert into a validated human dose. lab
- Tissue vs circulating peptide: Circulating EDG ≠ multi-week subjective breathing change; animal histology timelines from related lung peptides (often Bronchogen) should not be copy-pasted onto Chonluten PK. animal
More on what it is
- Cytogen vs Cytomax / Taxorest: Synthetic EDG capsules/vials are the Cytogen-style product; Taxorest and older Cytomax-style lung products are animal-tissue polypeptide complexes — same marketing family, not milligram-equivalent to lyophilized research EDG powder. forum
- Why people search it: COPD, asthma, post-viral lung, smoker/vaper residual symptoms, and multi-bioregulator “organ week” stacks — adjunct lore next to Bronchogen, not a drug swap. forum
- Sequence mix-up risk: Some vendor protocol pages mislabel Chonluten as Glu-Asp-Leu; reliable chem sheets and the 2022 paper materials list Glu-Asp-Gly (EDG). forum
- What it is: Synthetic tripeptide Glu-Asp-Gly (EDG / T-34); Khavinson-line bronchopulmonary bioregulator (Cytogen-class short peptide), not FDA- or EMA-approved as a respiratory drug. trial
- Chemistry talk: Vendor/chem sheets commonly list formula ~C₁₁H₁₇N₃O₈, MW ~319.27 g/mol, CAS ~75007-24-8; sequence is EDG, not a cartilage extract despite occasional blog title mix-ups. lab
- Mechanism claim (class): Ultrashort peptides may enter nuclei and modulate tissue gene expression (DNA/histone / methylation talk); class hypothesis from Khavinson reviews — not EDG-specific human pharmacology. lab
- Indexed Western experiment: One 2022 THP-1 monocyte paper (Avolio et al., co-authored with Khavinson) used ~100 ng/mL culture exposure — anti-inflammatory readout in immune cells, not airway epithelium or spirometry. lab
- Evidence posture: Almost no PubMed-indexed human RCTs named Chonluten; respiratory outcome claims largely trace to Russian observational/product literature and developer reviews without trial IDs. trial
- Not Bronchogen: Bronchogen is tetrapeptide Ala-Glu-Asp-Leu (AEDL) with denser rat COPD-model citations; animal COPD data online often belongs to AEDL, not EDG — do not transfer results. animal
- Not: Not an inhaler, oxygen, steroid, mucolytic, or proven COPD/asthma disease-modifying therapy. trial
Stacks
- Chonluten + Bronchogen (most common lung dual): Community frames Chonluten more as inflammation/gene-calm lore and Bronchogen more as bronchial-repair/COPD-model lore — complementary marketing, not a head-to-head trial. Ratios are not fixed; some run together, others sequential 10-day blocks with a short wash. forum
- Chonluten → Taxorest sequence: Synthetic cytogen “kickoff” for ~2–4 weeks then natural lung cytomax Taxorest (often discussed as 2 capsules daily before breakfast for another 1–2 months) appears in influencer and Cosmic-style threads. forum
- Full lung ladder (forum lore): Bronchogen course → short break → Chonluten course → short break → Taxorest cytomax — order and wash intervals vary by poster. forum
- Bioregulator kits / multi-organ weeks: With Epitalon (pineal), Vesugen (vascular), Vilon, Thymogen/Thymalin, Pinealon, Cartalax in “system-wide” packs — single-agent lung credit is weak inside kits. forum
- Repair crossover: BPC-157 and/or TB-500 for post-illness “body + lungs” stacks; high confound risk and no combo RCTs. forum
- GHK-Cu layer: Occasional post-COVID or remodeling talk pairs copper peptide with lung bioregulators — anecdote-level only. anecdote
- Respiratory lifestyle stack: NAC, vitamin D, omega-3s, hydration, pulmonary rehab, and smoking cessation appear beside peptide talk and often explain more variance than the peptide. forum
- Keep real care first: Continue inhalers, controllers, oxygen if prescribed, pulmonary rehab, and infection workups — peptide is adjunct lore only, never a substitute. forum
- Same-day multi-inject note: When stacking injectables, separate subq sites are commonly suggested; same-vial blends of unrelated peptides are convenience practice with unknown compatibility. forum
- Thymosin Alpha-1: Discussed with Chonluten for post-infectious immune + epithelial framing; some protocol blogs prefer sequential rather than simultaneous courses for cleaner tracking. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- GI upset (oral): Mild nausea or stomach discomfort sometimes reported with capsules. forum
- Injection-site: Redness, sting, itch, or irritation possible with subq research use — most consistent injectable complaint. forum
- Headache / nonspecific: Occasional headache or “off” first days mentioned; hard to separate from stacks or illness recovery. anecdote
- Allergy / hypersensitivity: Rare peptide product sensitivity possible (rash, itch); stop and reassess if systemic allergic signs appear. forum
- Pregnancy / breastfeeding: Not studied; standard research-peptide avoid language in secondary guides. forum
- Bronchogen / sequence mix-up: Expecting AEDL COPD-model results for EDG, or buying product labeled with the wrong sequence, is a practical research and self-experiment risk. forum
- Dose-chart chaos: 200 mcg short courses, 250–1,500 mcg multi-week charts, multi-mg bioregulator figures, and oral 10 mg capsules are not interchangeable — unit errors are a real harm vector. forum
- Source quality: Gray-market purity, underdosing, contamination, and short-peptide identity swaps. forum
- Don’t replace care: Progressive dyspnea, hypoxia, hemoptysis, or uncontrolled asthma/COPD need guideline workup; delaying care for a research peptide is the highest practical risk. forum
- Active smoking expectation: Some protocol summaries warn ongoing smoke exposure may overwhelm any theoretical epithelial support — cessation still dominates outcomes. forum
- WADA / sport: Not individually named on common WADA list summaries, but unapproved substances can still fall under catch-alls — not a clearance. forum
- Regulatory status: Research chemical / foreign bioregulator product — not an approved Western respiratory drug. forum
- Safety data gap: No solid human tox, interaction, or post-marketing safety dataset for research Chonluten; “well tolerated” marketing is not a Western clinical safety table. trial
- In-vitro apoptosis note: Culture work saw a mild increase in apoptotic THP-1 fraction with Chonluten vs some peers — not a mapped human adverse effect, but a reminder cell signals ≠ clinical safety. lab
- Not risk-free: Short-course bioregulator culture and “just three amino acids” framing do not remove purity, infection (injectable), or unknown long-horizon risks. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.